Executive Chairman, CEO and co-Founder
Carles obtained a BSs/MSc degree in biology (first class honors) from the Autonomous University of Barcelona and also a PhD degree in cellular biology from the same University, working at the Council of Science Research (CSIC). He has additional business training at ESADE business school and other business programs.
After his career in CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering Cancer Center in New York (1990-1992), he held senior positions at Almirall, SA (1992-2003) as Manager and Head of Business Development and Licensing and Lacer, SA (2005-2007) as Director, Business Development and Licensing.
Carles has also 4 years experience in biotech venture capital and business angels associations and has also been collaborating with government innovation agencies. Between 2004 and 2005 he was Director, Biotech Investments at the seed venture capital firm Barcelona Emprèn, SCRSA. During 2008-2009 he collaborated with agencies of the Government of Catalonia as Director, Technology Transfer and Valorization and as Managing Director, Investment and Enterprise Growth. He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Genesis Capital and Concept Capital. Since July 2009 he also advises Keiretsu Forum Barcelona in biotech investments.
In 2009 Carles cofounded Ability Pharmaceuticals, SL to become its Chief Executive Officer in September 2009
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
AbilityPharma is a clinical stage phase 2b biopharmaceutical company focused on autophagy to treat cancer
Your signup was successful. To complete the process of registering your first name, please refer to your email and confirm the email received from us.
We found a number of people with your first name. When you find your first name in this list, select it